ClinicalTrials.gg
Not yet recruitingNCT07877467FIL-BIO-IMGUpdated Oct 20, 2026

A Study to Compare the Pharmacokinetics, Pharmacodynamics, Immunogenicity, Safety and Tolerability of Filgrastim Biosimilar and Neupogen Reference Product in Healthy Volunteers

A Phase 1 interventional study of Biofilgragen and Neupogen (filgrastim) in Neutropenia (Low White Blood Cell Count), sponsored by BioGeneric Pharma. Not yet recruiting. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by BioGeneric Pharma · Phase 1, Interventional, and Other

Updated Oct 20, 2026Title changedNewly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 21 studies testing filgrastim in Neutropenia — 1 open to participants now, 1 under way, none of them phase 3. Filgrastim · Neutropenia.

Planned enrollment
16th of 19
50 · median 130
Started
2026
the only one that year
Phase 1
3 of 21
1 open now
Registered
21st of 21
by date
Lead sponsor
1 of 21
BioGeneric Pharma

Among the 21 studies testing filgrastim in Neutropenia, this one is the 16th largest by planned enrollment of the 19 interventional ones that give a count, is the only one that started in 2026, is one of 3 in phase 1, and was the 21st registered.

Neutropenia

316 studies on the registry are indexed under Neutropenia; 42 are open to participants now.

Browse Neutropenia studies →

Open to participants now

1 of the 21 studies testing filgrastim in Neutropenia is open now.

About filgrastim

Filgrastim: first FDA approval 1991 (NEUPOGEN), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 24 Neutropenia studies recruiting now, 12 (50%) set no upper age limit and 12 (50%) stop at 75 or younger; 11 take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing filgrastim in Neutropenia, or all of them as a file.
02

Study summary

The goal of this clinical trial is to assess the pharmacokinetic similarity of Biofilgragen, a filgrastim biosimilar, compared with EU-authorized Neupogen after single subcutaneous doses in healthy adult volunteers. The main questions it aims to answer are:

  • Are the maximum observed serum concentration (Cmax) and area under the serum concentration-time curve from time zero to infinity (AUC0-∞) of filgrastim similar between Biofilgragen and EU-authorized Neupogen?
  • What is the time to reach maximum observed serum concentration (tmax) and terminal elimination half-life (t½) following administration of each product? Researchers will compare Biofilgragen and EU-authorized Neupogen to assess pharmacokinetic similarity.

Participants will:

  • Receive a single 5 μg/kg subcutaneous dose of Biofilgragen and a single 5 μg/kg subcutaneous dose of EU-Neupogen in a randomized sequence during two treatment periods.
  • Receive each study product after an overnight fast, with the two treatment periods separated by a minimum 32-day washout period.
  • Provide blood samples at predefined time points after each dose to measure serum filgrastim concentrations and determine pharmacokinetic parameters.
  • Undergo safety assessments and monitoring throughout the study, including the follow-up period.
03

Conditions studied

  • Neutropenia (Low White Blood Cell Count)
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able and willing to provide written, dated prior to any study specific procedures.
  2. Able to comply with study procedures and visits for the entire study duration.
  3. Male or female, 18 to 55 years of age at the time of signing the informed consent.
  4. between 18.0 and 30.0 kg/m².
  5. Body weight 50-110 kg.
  6. Healthy as determined by medical history, physical examination, vital signs, 12-lead , laboratory assessments (biochemistry, hematology, urinalysis), and other screening evaluations, as applicable, with results within reference ranges or judged not by the Investigator.
  7. Hematology parameters, including (ANC), , count, and total white blood cell (WBC) count, within the laboratory reference ranges or considered clinically acceptable by the Investigator at screening.
  8. Female participants of must use highly effective (e.g., intrauterine device, hormonal implant, or a combined hormonal contraceptive) starting at least 4 weeks before first dosing and continuing until 4 weeks after the last study drug administration.
  9. Female participants of non childbearing potential must be either post menopausal (≥12 consecutive months of amenorrhea) or surgically sterile.

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or breastfeeding females.
  2. Known to filgrastim, other G-CSF products, Escherichia coli-derived proteins, or any of the study drugs.
  3. Known latex allergy.
  4. Known history or suspected Hereditary Fructose Intolerance (HFI).
  5. Known history, diagnosis, or screening evidence of Sickle Cell Disorder.
  6. Any clinically significant history or presence of cardiovascular, renal, pulmonary, neurological, musculoskeletal, hepatic, gastrointestinal, endocrinological, metabolic or psychiatric disease.
  7. Any clinically significant history or presence of hematologic disease (e.g., leukemia, myelodysplastic syndrome, aplastic anemia, chronic neutropenia, thrombocytopenia, coagulopathy).
  8. History or presence of clinically significant splenomegaly, splenic rupture, or splenectomy at screening.
  9. History or presence of clinically significant respiratory or pulmonary disease (such as moderate-to-severe asthma, , interstitial lung disease, pulmonary hypertension, acute respiratory distress syndrome [ARDS], or pulmonary hemorrhage) at screening.
  10. History or presence of clinically significant systemic or chronic inflammatory disease (such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vasculitis, or autoimmune thyroid disease requiring systemic therapy).
  11. History of alcohol abuse within 12 months prior to screening.
  12. Smokers who consume more than 10 cigarettes per day (or equivalent nicotine products).
  13. Receipt of any live or (e.g., MMR, varicella, yellow fever, oral typhoid) within 28 days prior to first study drug administration, or any inactivated, subunit, mRNA, or non-live vaccine (e.g., seasonal influenza, hepatitis A/B, tetanus, COVID-19) within 14 days prior to the first study drug administration.
  14. Positive test results for drugs of abuse screening in urine at screening or before each treatment period.
  15. Positive test results at screening for surface antigen (HBsAg, serum), or combined antigen/antibody (HIV Ag-Ab, serum). Participants with a positive virus antibody (HCV Ab, serum) result will undergo confirmatory PCR testing and may be eligible if the PCR result is negative.
  16. Positive pregnancy test for females of at screening or before each treatment period.
  17. Whole blood donation more than 400 mL or significant acute blood loss within 8 weeks prior to screening.
  18. Plasma, , or apheresis donation within 4 weeks prior to screening.
  19. Prior use of granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), or other hematopoietic growth factors within 3 months prior to the first study drug administration.
  20. Prior use of erythropoiesis-stimulating agents within 3 months prior to the first study drug administration.
  21. Use of systemic or other within 30 days prior to the first study drug administration.
  22. Prior use of biological immunomodulators (such as tumor necrosis factor [TNF] inhibitors) within 3 months or 5 elimination half-lives (whichever is longer) prior to the first study drug administration.
  23. Prior use of cytotoxic or antimetabolite agents within 30 days prior to the first study drug administration.
  24. Participation in another interventional clinical trial involving administration of an medicinal product, or receipt of an investigational medicinal product, within 90 days or 5 elimination half-lives (whichever is longer) prior to the first study drug administration
  25. Use of any other prescription or OTC medication, herbal product, vitamin, or dietary supplement that, in the Investigator's judgment, may affect hematopoiesis, immune function, filgrastim pharmacokinetics/pharmacodynamics, or study safety assessments within 14 days or 5 elimination half-lives (whichever is longer) prior to the first study drug administration.
  26. Any psychiatric, cognitive, or other condition that, in the investigator's opinion, could compromise the participant's ability to give truly , comply with study procedures, or safely complete the study.
  27. Any other condition or circumstance that, in the Investigator's medical judgment, renders the participant unsuitable for participation in the study.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    TR

    Participants randomized to this sequence will receive a single subcutaneous dose of Biofilgragen (Test) during Period 1, followed by a single subcutaneous dose of EU-authorized Neupogen (Reference/active comparator) during Period 2, with the specified washout period between treatments.

    Drug: Biofilgragen · Drug: Neupogen (filgrastim)

  • Experimental
    RT

    Participants randomized to this sequence will receive a single subcutaneous dose of EU-authorized Neupogen (Reference/active comparator) during Period 1, followed by a single subcutaneous dose of Biofilgragen (Test) during Period 2, with the specified washout period between treatments.

    Drug: Biofilgragen · Drug: Neupogen (filgrastim)

Interventions

  • DrugBiofilgragen

    Biofilgragen is a filgrastim biosimilar and recombinant human granulocyte colony-stimulating factor (G-CSF). It will be administered as a single subcutaneous injection at a dose of 5 mcg/kg. Biofilgragen is intended to mirror the reference product in amino acid sequence, formulation, route of administration, and dosing schedule and to engage the same G-CSF receptor-mediated mechanisms.

  • Neupogen is the EU-authorized reference medicinal product containing filgrastim. It will be administered as a single subcutaneous injection at a dose of 5 mcg/kg under the same conditions as Biofilgragen. It serves as the active comparator for the biosimilar comparison and has well-characterized pharmacokinetic, pharmacodynamic, safety, and immunogenicity profiles.

06

What researchers measure

Primary outcomes

  1. Maximum observed serum filgrastim concentration (Cmax)

    To compare the maximum observed serum filgrastim concentration (Cmax) following administration of Biofilgragen (test product) and EU-authorized Neupogen (reference product). Serum filgrastim concentrations will be measured using a validated enzyme-linked immunosorbent assay (ELISA) from serial blood samples collected at the protocol-specified pharmacokinetic sampling time points. Cmax will be derived using non-compartmental analysis. Pharmacokinetic similarity will be assessed using the two-sided 90% confidence interval for the test-to-reference geometric mean ratio, with acceptance limits of 80% to 125%.

    Time frame: Pre-dose (-0.5 h) and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, and 24 hours post-dose, in each treatment period.

  2. Time to reach maximum observed serum filgrastim concentration (tmax) (hours)

    To determine the time to reach the maximum observed serum filgrastim concentration (tmax) following administration of Biofilgragen and EU-authorized Neupogen. The parameter will be derived from the serum concentration-time profile using non-compartmental analysis and expressed in hours. Results will be summarized descriptively.

    Time frame: Pre-dose (-0.5 h) and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, and 24 hours post-dose, in each treatment period.

  3. Area under the serum filgrastim concentration-time curve from time zero to infinity (AUC0-inf)

    To compare the area under the serum filgrastim concentration-time curve from time zero extrapolated to infinity (AUC0-inf) following administration of Biofilgragen and EU-authorized Neupogen. The parameter will be calculated from serial serum concentration measurements using non-compartmental analysis. Pharmacokinetic similarity will be assessed using the two-sided 90% confidence interval for the test-to-reference geometric mean ratio, with acceptance limits of 80% to 125%.

    Time frame: Pre-dose (-0.5 h) and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, and 24 hours post-dose, in each treatment period; AUC extrapolated to infinity.

  4. Terminal elimination half-life of serum filgrastim (t½) (hours)

    To determine the terminal elimination half-life (t1/2) of serum filgrastim following administration of Biofilgragen and EU-authorized Neupogen. The parameter will be derived from the serum concentration-time profile using non-compartmental analysis and expressed in hours. Results will be summarized descriptively.

    Time frame: Pre-dose (-0.5 h) and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, and 24 hours post-dose, in each treatment period.

Secondary outcomes

  1. Maximum observed absolute neutrophil count (ANCmax) (cells/µL)

    To compare the maximum observed absolute neutrophil count (ANCmax) following administration of Biofilgragen and EU-authorized Neupogen. ANC will be measured using a validated automated hematology analyzer, and ANCmax will be derived from serial ANC measurements collected at the protocol-specified pharmacodynamic sampling time points.

    Time frame: Pre-dose (-0.5 h) and 4, 8, 10, 12, 16, 24, 36, 48, 72, and 96 hours post-dose, in each treatment period.

  2. Time to maximum observed absolute neutrophil count (time to ANCmax) (hours)

    To determine the time to reach the maximum observed absolute neutrophil count (tmax, ANC) following administration of Biofilgragen and EU-authorized Neupogen. The parameter will be derived from serial ANC measurements and expressed in hours.

    Time frame: Pre-dose (-0.5 h) and 4, 8, 10, 12, 16, 24, 36, 48, 72, and 96 hours post-dose, in each treatment period.

  3. Area under the absolute neutrophil count-time curve from time zero to 96 hours (AUEC0-96h)

    To compare the area under the absolute neutrophil count-time curve from time zero to 96 hours post-dose (AUEC0-96h) following administration of Biofilgragen and EU-authorized Neupogen. The parameter will be calculated from serial ANC measurements collected during the 96-hour post-dose assessment period.

    Time frame: Pre-dose (-0.5 h) and 4, 8, 10, 12, 16, 24, 36, 48, 72, and 96 hours post-dose, in each treatment period.

  4. Incidence of treatment-emergent anti-drug antibodies (ADA)

    To evaluate the incidence of treatment-emergent anti-drug antibodies (ADA) against filgrastim following administration of Biofilgragen and EU-authorized Neupogen. Treatment-emergent ADA will be defined as a negative baseline ADA result followed by one or more confirmed positive ADA results after treatment. ADA will be assessed using the study-specified validated immunogenicity testing method. Results will be summarized by the number and percentage of participants meeting the definition.

    Time frame: Predose in Treatment Period 1 (baseline), predose in Treatment Period 2, and at the final Follow-up visit (Day 69 + 7 days).

  5. Incidence of neutralizing antibodies (NAb)

    To evaluate the incidence of neutralizing antibodies (NAb) against filgrastim following administration of Biofilgragen and EU-authorized Neupogen. NAb testing will be performed for confirmed ADA-positive samples, where applicable, using the study-specified neutralizing antibody assay. Results will be summarized by the number and percentage of participants with detected neutralizing antibodies.

    Time frame: Predose in Treatment Period 1 (baseline), predose in Treatment Period 2, and at the final Follow-up visit (Day 69 + 7 days).

  6. Incidence, severity, and relationship to study treatment of adverse events (AEs)

    To evaluate the incidence, severity, and relationship to study treatment of adverse events (AEs) following administration of Biofilgragen and EU-authorized Neupogen. AEs will be recorded, assessed, and classified according to the study protocol, including assessment of severity and relationship to study treatment. Events will be coded using the Medical Dictionary for Regulatory Activities (MedDRA), Version 29.0. Results will be summarized by the number and percentage of participants experiencing AEs, with severity and relationship reported as applicable.

    Time frame: From signing the Informed Consent Form through the final Follow-up visit (Day 69 + 7 days).

  7. Incidence, severity, and relationship to study treatment of serious adverse events (SAEs)

    To evaluate the incidence, severity, and relationship to study treatment of serious adverse events (SAEs) following administration of Biofilgragen and EU-authorized Neupogen. SAEs will be recorded, assessed, and classified according to the study protocol and coded using the Medical Dictionary for Regulatory Activities (MedDRA), Version 29.0. Results will be summarized by the number and percentage of participants experiencing SAEs, with severity and relationship to study treatment reported as applicable.

    Time frame: From signing the Informed Consent Form through the final Follow-up visit (Day 69 + 7 days).

  8. Incidence of adverse events of special interest (AESIs)

    To evaluate the incidence of adverse events of special interest (AESIs), including splenic events, pulmonary events, capillary leak syndrome, vasculitis, glomerulonephritis, and hypersensitivity reactions. AESIs will be recorded and assessed according to the study protocol and coded using the Medical Dictionary for Regulatory Activities (MedDRA), Version 29.0. Results will be summarized by the number and percentage of participants experiencing AESIs.

    Time frame: From signing the Informed Consent Form through the final Follow-up visit (Day 69 + 7 days).

  9. Physical examination findings

    To assess physical examination findings following the protocol-specified complete physical examination, covering general appearance; head, eyes, ears, nose, and throat; cardiovascular, respiratory, abdominal, musculoskeletal, neurologic, and skin systems. Findings will be documented and clinically significant abnormalities will be evaluated according to the study protocol.

    Time frame: Screening, Treatment Periods 1 and 2, and at the final Follow-up visit (Day 69 + 7 days).

  10. Change in Systolic Blood Pressure from Baseline (mmHg)

    To evaluate systolic blood pressure following administration of Biofilgragen and EU-authorized Neupogen. Systolic blood pressure will be measured using the protocol-specified standardized vital-sign assessment procedure and recorded in millimeters of mercury (mmHg). Changes and clinically significant findings will be assessed according to the study protocol.

    Time frame: Screening, Treatment Periods 1 and 2, and at the final Follow-up (Day 69 + 7 days).

  11. Change in Diastolic Blood Pressure from Baseline (mmHg)

    To evaluate diastolic blood pressure following administration of Biofilgragen and EU-authorized Neupogen. Diastolic blood pressure will be measured using the protocol-specified standardized vital-sign assessment procedure and recorded in millimeters of mercury (mmHg). Changes and clinically significant findings will be assessed according to the study protocol.

    Time frame: Screening, Treatment Periods 1 and 2, and at the final Follow-up (Day 69 + 7 days).

  12. Change in Heart Rate from Baseline (beats/minute)

    To evaluate heart rate following administration of Biofilgragen and EU-authorized Neupogen. Heart rate will be measured using the protocol-specified standardized vital-sign assessment procedure and recorded in beats per minute. Changes and clinically significant findings will be assessed according to the study protocol.

    Time frame: Screening, Treatment Periods 1 and 2, and at the final Follow-up (Day 69 + 7 days).

  13. Change in Respiratory Rate from Baseline (breaths/minute)

    To evaluate respiratory rate following administration of Biofilgragen and EU-authorized Neupogen. Respiratory rate will be measured using the protocol-specified standardized vital-sign assessment procedure and recorded in breaths per minute. Changes and clinically significant findings will be assessed according to the study protocol.

    Time frame: Screening, Treatment Periods 1 and 2, and at the final Follow-up (Day 69 + 7 days).

  14. Change in Body Temperature from Baseline (°C)

    To evaluate body temperature following administration of Biofilgragen and EU-authorized Neupogen. Body temperature will be measured using the protocol-specified vital-sign assessment procedure and recorded in degrees Celsius (°C). Changes and clinically significant findings will be assessed according to the study protocol.

    Time frame: Screening, Treatment Periods 1 and 2, and at the final Follow-up (Day 69 + 7 days).

  15. 12-lead resting electrocardiogram (ECG) findings

    To assess cardiac findings using a 12-lead resting electrocardiogram (ECG) performed according to the study protocol. ECG findings will be reviewed and documented, and clinically significant abnormalities will be evaluated by the Investigator.

    Time frame: Screening and at the final Follow-up visit (Day 69 + 7 days).

  16. Chest X-Ray Findings

    To assess pulmonary findings using chest X-ray examinations performed according to the study protocol. Findings will be reviewed and documented, and clinically significant abnormalities will be evaluated by the Investigator.

    Time frame: Screening and at the final Follow-up visit (Day 69 + 7 days).

  17. Abdominal ultrasound findings, including spleen assessment

    To assess abdominal ultrasound findings, including spleen assessment, using the protocol-specified ultrasonography examination. Findings will be reviewed and documented, and clinically significant abnormalities will be evaluated by the Investigator.

    Time frame: Screening, within 7 days prior to dosing in Treatment Period 2 and at the final Follow-up visit (Day 69 + 7 days).

  18. Changes in Clinical Laboratory Parameters from Baseline

    To evaluate changes in clinical laboratory parameters from baseline following administration of Biofilgragen and EU-authorized Neupogen. Clinical laboratory assessments will include: 1. Hematology: Hemoglobin, Hematocrit, MCH, MCHC, MCV, RBC, Platelet Count, WBC Count, and Differential WBCs. 2. Renal Function: Urea, Creatinine, BUN, and Uric Acid. 3. Electrolytes: Sodium and Potassium. 4. Liver Function: GGT, ALT, AST, Bilirubin, Alkaline Phosphatase, Total Bilirubin, and Direct Bilirubin. 5. Bone and Protein Metabolism: Calcium, Total Protein, and Albumin. 6. Other Laboratory Parameters: Random Blood Glucose, Cholesterol, FT4, and TSH. 7. Urinalysis: Colour, Aspect, pH, Specific Gravity, Glucose, Ketone Bodies, Bilirubin, Urobilinogen, Albumin, Pus Cells, Red Blood Cells, Epithelial Cells, Crystals, Amorphous Materials, Casts, Parasites, and Yeast Cells.

    Time frame: Screening, within 7 days prior to dosing in Treatment Period 2 and at the final Follow-up visit (Day 69 + 7 days).

  19. Local tolerability at injection site

    To evaluate local tolerability at the injection site following administration of Biofilgragen and EU-authorized Neupogen. Injection-site reactions will be assessed and recorded according to the study protocol. Reported injection-site reactions will be followed through the final Follow-up visit.

    Time frame: Following each study treatment administration during both treatment periods, with follow-up of any reported injection-site reactions through the final follow-up visit on Day 69 (±7 days).

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2026; primary completion for Apr 2027, 3 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 4, 2026
First posted
Oct 16, 2026
StartEst.
Dec 15, 2026
Primary completionEst.
Apr 7, 2027
CompletionEst.
May 21, 2027
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Title
A Study to Compare the PK and PDPharmacokinetics, Pharmacodynamics, Immunogenicity, Safety and Tolerability of Filgrastim Biosimilar and Neupogen Reference Product in Healthy Volunteers
Oct 20, 2026
Registered
First appeared on the registry
Oct 16, 2026
Show all 2 updates
  1. Oct 20, 2026
    Title A Study to Compare the PK and PDPharmacokinetics, Pharmacodynamics, Immunogenicity, Safety and Tolerability of Filgrastim Biosimilar and Neupogen Reference Product in Healthy Volunteers
  2. Oct 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07877467
Lead sponsor
BioGeneric Pharma
Responsible party
Sponsor
First posted
Oct 16, 2026
Start date
Dec 15, 2026 (estimated)
Primary completion
Apr 7, 2027 (estimated)
Completion
May 21, 2027 (estimated)
Last update
Oct 20, 2026

Study contacts

Merna Michel
Contact
mirna.michael@marc-eg.org
+201220229278
Lydia Bahig
Contact
lydia.bahig@marc-eg.org
+201225952401

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Filgrastim

Start the discussion